Dr Lee Borthwick (Chief Operations Officer of Fibrofind), leads new project aimed at developing a human tissue slice based cardiac fibrosis model to replace certain rodent studies.

We are delighted to announce that FibroFind have been shortlisted for the prestigious Bionow Export Award for 2022.

The Bionow Awards Dinner & Ceremony is a highlight of our sector, celebrating individuals and companies who have made real impact across the year and showcasing the very best of our industry.

The event to be held beneath the wings of Concorde in March 2023 is set to be a fantastic evening and all of FibroFind will be holding our breath when the envelope is opened.

FibroFind are pleased to announce our attendance at the CKD Summit in Boston, Massachusetts on 7-9^th March 2023.

This 5^th Chronic Kidney Disease Drug Development Summit has been described as “powerful” by previous attendees with an excellent range of key players speaking on the hottest topics in this field from a Pharma and Biotech perspective.

Our own Dr Lee Borthwick, Chief Operating  Officer at FibroFind will be exploring the following topics as a speaker on day 2 of the conference;

• Human precision cut kidney slices (PCKS) retain the cellular complexity and architecture of the native tissue in culture
• Established, dynamic models of tissue inflammation and fibrogenesis in PCKS
• Application of PCKS for drug testing, target engagement and assessment of tissue viability

Please attend along and join the conversation by following the link 

Thank you to all who attended our 2022 AGM, held on the 15th November 2022.

Despite difficult times in many sectors 2021 / 2022 was another year of incredible growth for FibroFind, showing an excellent financial return alongside technical advancements and increasing our Global footprint and client base. Our team has also grown, bringing in new areas of expertise which will support our planned expansion both technically and from a business point of view.

The opening of our Istanbul branch has brought an opportunity to focus on R&D with a dedicated team of professionals focussing on the future of preclinical drug development.

We look forward to another hugely successful year with many exciting new developments in our journey…. Watch this space!

FibroFind are extremely proud of the technology we have developed inhouse to support our unique position in the market.

We have created two new videos for Liver and Kidney which explain our patented PCS (Precision Cut Slice) Technology which can be found on the ‘Solutions’ page of this website. Click below to view our Liver video with the Kidney model to follow shortly.

Please join us in welcoming Ben Gilhespy to the executive team.

To support our continued growth it was recognised that a business person was needed to look after the none technical aspects of FibroFind, allowing the team to concentrate on developing into new markets, technologies and geographies.

Ben has spent many years supporting sme’s in their growth whilst working on a wide range of boards across most sectors, so was an ideal fit for FibroFind. He said that “this is an incredible business who have developed into an exciting market. They have taken their years of academic expertise into the commercial arena, forging relationships with some of the worlds leading companies in the field of drug development. To say that I am proud to join the team and be a part of this amazing business is an understatement.”

Receiving external recognition for the success of a business is always a proud moment and FibroFind are extremely excited to announce that we have been awarded ‘Start up of the Year 2021’ at the recent Bionow Awards hosted in 2022.This award follows a year of significant growth despite turbulent international markets.

Bionow identified FibroFind as a preclinical drug development organisation specialising in fibrosis and chronic disease who use innovative approaches to develop biomedical services, equipment or products particularly those which serve the needs of human healthcare.

A very proud moment for a great team.

The whole team is extremely proud of being shortlisted in two categories for the Bionow Awards 2021: Bionow Start-Up of the Year and Bionow Export Award!

This nomination is the result of the daily dedication and passion of our amazing team for the delivery of outstanding services.

The whole team is so excited and will attend the award ceremony on March 31st, at the Concorde Conference Centre. Fingers Crossed!

ECM 2022, held on 23-25 June 2022 is the first international extracellular matrix pharmacology congress.

"The aim of the ECM2022 congress is to focus on development of new drugs targeting the extracellular matrix and improve our understanding of changes to the extracellular matrix across chronic diseases."

Source: https://ecm-congress.org/

Hepion Pharmaceuticals announced the results of a nonclinical research study conducted with Fibrofind showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer.

Additionally, CRV431 was as effective at decreasing tumor burden as an anti-PD1 antibody immune checkpoint inhibitor, PD1 antibody, and produced more beneficial changes in tumor-infiltrating cells compared to anti-PD1 antibody treatment.

FibroFind is proud to share the poster showing the results of a study carried out for one of our clients, a major pharmaceutical company, Gilead Sciences, Inc.

The poster was originally displayed at the recent European Association for the Study of the Liver (EASL) annual meeting (ILC2021). Using its patented bioreactor and human precision-cut tissue slices (PCLS), FibroFind have tested Gilead’s novel compound in a setting of fatty liver.

Based on the data collected from three human donors, Gilead conclude in the summary of the poster “these data are similar to improvements in steatosis and fibrosis observed in patients with NASH treated with FIR and CILO combination therapy, and suggest human PCLS as a promising translational model to evaluate future NASH therapies”

FibroFind collaborates to discover mTORC1-Plin3-regulated lipophagy protects against fatty liver disease.

We are excited to announce the publication of an important collaborative study with the Newcastle Fibrosis Research Group where we applied our precision-cut liver slice (PCLS) bioreactor technology to discover a naturally occurring mechanism that guards against the unhealthy build-up of fat in hepatocytes which affects up to 1 billion people worldwide and can lead to chronic liver disease and/or development of liver cancer.

​Neutrophils induce paracrine telomere dysfunction and senescence in a ROS-dependant manner.

Derek Mann, Chief Scientific Officer, explains that the use Fibrofind's PCLS Technology "adds an important human science angle to a story about how neutrophils which are perhaps the most important cells for tackling infections, promote tissue ageing".

This paper is published in The EMBO Journal is accessible under Open Souce Licence.

Our CEO, Jelena Mann, will present our Precision-Cut Liver Slice technology at the 4th Annual NASH Summit and its use in the preclinical phase of the Drug Development process.

Click below to learn more about the NASH summit or contact us to enquire about the PCLS technology and our related services.

On November 17th, 2020, Dr Lee Borthwick, our Chief Operation Officer presented our patented Pricesion-Cut Slice technology and its use for the modelling of Fibrosis in pre-clinical trials at 4th Annual AFDD summit.

If you missed this talk and want to know more about the PCS technology get in touch with us!

On November 9th 2020, Nature Metabolism has published an article resulting from a research project led by the Newcastle Fibrosis Research Group that uses Fibrofind's Precision-cut Liver Slices technology.

The paper entitled "c-Rel orchestrates energy-dependent epithelial and macrophage reprogramming in fibrosis"

The complete article is available on open access.

A shareholders meeting will be held on Thursday, September 17th 2020, from 12:00 to 12:30 to discuss and approve the following resolution:

- Resolution 1: The transfer of the intellectual property from Fibrofind Ltd to Fibrofind IP Ltd.

All shareholders are invited to contact Jeremy Domis (jeremy.domis@fibrofind.com) to receive information about the location of the meeting.

In a new study ran for Hepion's Pharmaceuticals, Fibrofind demonstrate that Hepion's drug candidate, CRV431, first tested on Liver shows efficacy on idiopathic pulmonary fibrosis.

Jelena Mann and Lee Borthwick, respectively CEO and COO of Fibrofind will be present and present our Precision-Cut Slice technology at the 4th Annual NASH Summit

From February 19-23, three of our directors attended Keystone Symposia on Fibrosis and Tissue Repair, with our COO, Dr. Lee Borthwick, presenting our Precision-Cut Slice technology

Read our Precision-Cut Liver Slice technology paper published in Hepatology Journal

​Hepion Pharmaceutical's NASH drug shows remarkable efficacy in a Precision-cut Liver slice Study on human tissue preformed by Fibrofind

Great results on testing its CRV431 compound in a Fibrofind PCLS Study leads to impressive results on Hepion's value on the Nasdaq Stock Exchange

Last September, Vicore Pharma Holding a clinical-stage pharmaceutical company announced the positive results obtained testing their drug candidate VP01 on IPF lung tissue using Fibrofind's Precision-Cut Slices platform.